We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

230 hedge funds and large institutions have $561M invested in Nektar Therapeutics in 2022 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 70 increasing their positions, 74 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

814% more call options, than puts

Call options by funds: $2M | Put options by funds: $219K

20% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 25

1% more funds holding

Funds holding: 227 → 230 (+3)

0.3% less ownership

Funds ownership: 6.53% → 6.24% (-0.3%)

5% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 74

19% less capital invested

Capital invested by funds: $693M → $561M (-$131M)

Holders
230
Holders Change
+3
Holders Change %
+1.32%
% of All Funds
3.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
70
Reduced
74
Closed
25
Calls
$2M
Puts
$219K
Net Calls
+$1.78M
Net Calls Change
-$1.41M

Top Buyers

1
BlackRock
BlackRock
New York
+$13.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$10.2M
3
Northern Trust
Northern Trust
Illinois
+$3.87M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$3.21M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$2.89M

Top Sellers

1
First Trust Advisors
First Trust Advisors
Illinois
-$29.8M
2
MC
Maverick Capital
Texas
-$12.2M
3
GPP
Great Point Partners
Connecticut
-$10.7M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$4.33M
5
State Street
State Street
Massachusetts
-$3.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRSOTSOK
101
Teachers Retirement System of the State of Kentucky
Kentucky
$198K +$245K +4,126 New
OPERF
102
Oregon Public Employees Retirement Fund
Oregon
$196K +$535 +9 +0.2%
GCP
103
GSA Capital Partners
United Kingdom
$190K +$74.8K +1,257 +47%
SAM
104
Storebrand Asset Management
Norway
$186K -$175K -2,941 -43%
AP
105
Adero Partners
California
$184K – – –
SO
106
STRS Ohio
Ohio
$181K – – –
Franklin Resources
107
Franklin Resources
California
$168K +$209K +3,515 New
DTL
108
Dynamic Technology Lab
Singapore
$166K +$206K +3,464 New
CANY
109
Caxton Associates (New York)
New York
$162K -$251K -4,225 -56%
ASRS
110
Arizona State Retirement System
Arizona
$162K +$2.44K +41 +1%
CM
111
CM Management
Florida
$160K -$297K -5,000 -60%
ECM
112
Everence Capital Management
Indiana
$153K – – –
QT
113
Quantbot Technologies
New York
$152K +$177K +2,979 +1,536%
Osaic Holdings
114
Osaic Holdings
Arizona
$147K +$773 +13 +0.4%
Ohio Public Employees Retirement System (OPERS)
115
Ohio Public Employees Retirement System (OPERS)
Ohio
$144K – – –
EAM
116
Erste Asset Management
Austria
$142K – – –
VCP
117
Verus Capital Partners
Arizona
$131K +$163K +2,734 New
ProShare Advisors
118
ProShare Advisors
Maryland
$130K -$9.58K -161 -6%
Victory Capital Management
119
Victory Capital Management
Texas
$130K +$21.5K +361 +15%
XT
120
XTX Topco
Cayman Islands
$126K +$36.6K +615 +31%
MOACM
121
Mutual of America Capital Management
New York
$119K +$23.8K +400 +19%
SLAM
122
Swiss Life Asset Management
$114K +$8.45K +142 +6%
KA
123
Klingman & Associates
New York
$114K +$141K +2,372 New
Rafferty Asset Management
124
Rafferty Asset Management
New York
$108K -$150K -2,519 -53%
Marshall Wace
125
Marshall Wace
United Kingdom
$100K +$124K +2,076 New
3 4
5
6 7

NKTR Hedge Fund Activity: Q3 2022 in Review

230 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2022, worth a combined $561M — down 19% from $693M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new NKTR positions and 25 closed out — a net gain of 5 holders — while 70 added to existing stakes and 74 trimmed.

The largest buyer was BlackRock, adding an estimated $13.8M. The largest seller was First Trust Advisors, exiting entirely with an estimated $29.8M sold.

  • 230 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2022, up from 227 in Q2 2022.
  • Funds reported $561M of Nektar Therapeutics stock for Q3 2022, down 19% quarter-over-quarter.
  • 30 funds opened new Nektar Therapeutics positions in Q3 2022 and 25 closed out, a net change of +5 holders.
  • The largest Nektar Therapeutics buyer in Q3 2022 was BlackRock, an estimated $13.8M added.
  • The largest Nektar Therapeutics seller in Q3 2022 was First Trust Advisors, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2022.